DNMT3B and chronic kidney disease: The expression levels of EZH2 and DNMT3B were decreased in stage IV-V CKD patients; however, expression increased under PD treatment, and PD therapy in 5/6Nx rats induced EZH2 and DNMT3B expression significantly, which indicated that epigenetic mechanisms involving EZH2 and DNMT3B might play crucial roles in peritoneum angiogenesis and remodelling in PD.